Haselnuß Bencard Allergie (Hazelnut)

Haselnuß Bencard Allergie is employed primarily for in‑clinic diagnostic testing of hazelnut allergy.

• Screening patients with suspected hazelnut allergy.
• Confirming sensitization after a positive skin prick test.
• Supporting allergists in differentiating true allergy from tolerance.
• Guiding dietary advice and avoidance strategies.
• Assisting in research protocols involving hazelnut allergen exposure.

Side effects from intraepidermal hazelnut testing are generally mild, but clinicians should monitor for both common and rare reactions.

Common

• Local redness at the test site.
• Mild swelling or papule formation.
• Itching or transient discomfort.
• Small wheal formation that resolves within 30 minutes.

Serious

• Systemic urticaria or hives.
• Angioedema affecting lips, eyes, or airway.
• Anaphylactic reaction requiring emergency treatment.
• Severe bronchospasm or respiratory distress.

When using Haselnuß Bencard Allergie, healthcare providers should observe several precautions to ensure patient safety.

• Verify patient history for prior severe reactions to hazelnut.
• Perform testing in a setting equipped for emergency management.
• Use a standardized concentration and technique as recommended.
• Observe the patient for at least 30 minutes after administration.
• Document any adverse response and report serious events.
• Avoid testing in patients on high‑dose antihistamines that may mask reactions.

Certain medications and conditions can influence the outcome of hazelnut allergen testing or increase risk of adverse events.

Avoid

• Beta‑blockers, which may worsen anaphylaxis management.
• ACE inhibitors that can potentiate angioedema.
• Recent systemic corticosteroid therapy that may suppress skin reactivity.

Use with caution

• Antihistamines, which may reduce test sensitivity; consider temporary discontinuation.
• Immunotherapy targeting nut allergens, as it may alter skin test results.
• Acute infections or dermatologic conditions at the test site.